1. |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
|
2. |
Zheng RS, Zhang SW, Zeng HM, et al. Cancer incidence and mortality in China, 2016. J Natl Cancer Cent, 2022, 2: 1-9.
|
3. |
Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 2019, 394(10204): 1145-1158.
|
4. |
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
|
5. |
Fan R, Papatheodoridis G, Sun J, et al. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. J Hepatol, 2020, 73(6): 1368-1378.
|
6. |
Allemani C, Weir HK, Carreira H, et al. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet, 2015, 385(9972): 977-1010.
|
7. |
国家卫生健康委办公厅. 原发性肝癌诊疗指南 (2022 年版). 临床肝胆病杂志, 2022, 38(2): 288-303.
|
8. |
中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范 (2019年版). 临床肝胆病杂志, 2020, 36(2): 277-292.
|
9. |
Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med, 2020, 382(20): 1894-1905.
|
10. |
Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 2008, 359(4): 378-390.
|
11. |
Qin S, Bai Y, Lim HY, et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol, 2013, 31(28): 3501-3508.
|
12. |
Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase Ⅲ randomised, double-blind, placebo-controlled trial. Lancet Oncol, 2009, 10(1): 25-34.
|
13. |
Qin S, Bi F, Gu S, et al. Donafenib versus sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma: a randomized, open-label, parallel-controlled phase Ⅱ–Ⅲ trial. J Clin Oncol, 2021, 39(27): 3002-3011.
|
14. |
Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet, 2018, 391(10126): 1163-1173.
|
15. |
Ren Z, Xu J, Bai Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study. Lancet Oncol, 2021, 22(7): 977-990.
|
16. |
Qin S, Ren Z, Meng Z, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol, 2020, 21(4): 571-580.
|
17. |
Ren Z, Qin S, Meng Z, et al. A phase 2 study of camrelizumab for advanced hepatocellular carcinoma: two-year outcomes and continued treatment beyond first RECIST-defined progression. Liver Cancer, 2021, 10(5): 500-509.
|
18. |
Abou-Alfa GK, Chan SL, Kudo M, et al. A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study. J Clin Oncol, 2018, 36(15): TPS4144. doi: 10.1200/jco.2018.36.15_suppl.tps4144.
|
19. |
Sun Y, Qin SK, Li W, et al. A randomized, double-blinded, phase Ⅲ study of icaritin versus huachashu as the first-line therapy in biomarker-enriched HBV-related advanced hepatocellular carcinoma with poor conditions: interim analysis result. J Clin Oncol, 2021, 39(15 suppl): abstract 4077. doi: 10.1200/JCO.2021.39.15_suppl.4077.
|
20. |
成远, 华海清. 榄香烯治疗原发性肝癌的研究进展. 临床肿瘤学杂志, 2017, 22(10): 950-953.
|
21. |
童光武, 高鹏. 消癌平注射液联合榄香烯注射液治疗中晚期原发性肝癌的临床研究. 现代药物与临床, 2016, 31(5): 691-695.
|
22. |
陈乃杰, 吴丹红, 赖义勤, 等. 消癌平联合化疗治疗中晚期肝癌的临床分析. 光明中医, 2009, 24(6): 1111-1112.
|
23. |
Ducreux M, Abou-Alfa Gk, Ren Z, et al. Results from a global phase 2 study of tislelizumab, an investigational PD-1 antibody, in patients with previously treated advanced hepatocellular carcinoma. Ann Oncol, 2021, 32(3s): s217.
|
24. |
Qin S, Chen Z, Fang W, et al. Pembrolizumab versus placebo as second-line therapy in patients from Asia with advanced hepatocellular carcinoma: a randomized, double-blind, phase Ⅲ trial. J Clin Oncol, 2022: JCO2200620. doi: 10.1200/JCO.22.00620.
|
25. |
Mei K, Qin S, Chen Z, et al. Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ⅰb/Ⅱ trial. J Immunother Cancer, 2021, 9(3): e002191. doi: 10.1136/jitc-2020-002191.
|
26. |
中华医学会肝病学分会肝癌学组. HBV/HCV相关肝细胞癌抗病毒治疗专家共识 (2021年更新版). 临床肝胆病杂志, 2021, 37(10): 2292-2302.
|
27. |
中华医学会肝病学分会肝炎学组, 中华肝脏病杂志. 非一线核苷 (酸) 类似物经治慢性乙型肝炎患者治疗策略调整专家共识. 中华肝脏病杂志, 2019, 27(5): 343-346.
|
28. |
Papatheodoridis GV, Idilman R, Dalekos GN, et al. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. Hepatology, 2017, 66(5): 1444-1453.
|
29. |
Pawlotsky JM, Negro F, Aghemo A, et al. European association for the study of the liver. EASL recommendations on treatment of hepatitis C 2014. J Hepatol, 2014, 61(2): 373-395.
|
30. |
邱福南, 王耀东, 田毅峰, 等. 阿德福韦酯联合胸腺肽α1对HBV感染肝细胞癌术后疗效的影响. 中华临床医师杂志 (电子版), 2010, 4(3): 278-283.
|
31. |
Kim WR, Loomba R, Berg T, et al. Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B. Cancer, 2015, 121(20): 3631-3638.
|
32. |
Buti M, Gane E, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol, 2016, 1(3): 196-206.
|
33. |
Chan HL, Fung S, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol, 2016, 1(3): 185-195.
|
34. |
Huang G, Lau WY, Wang ZG, et al. Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial. Ann Surg, 2015, 261(1): 56-66.
|
35. |
中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南 (2019年版). 中华传染病杂志, 2019, 37(12): 711-736.
|
36. |
中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南 (2019年版). 中华临床感染病杂志, 2019, 12(6): 429-450.
|
37. |
Liu Z, Jin Q, Zhang Y, et al. Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B. Aliment Pharmacol Ther, 2021, 54(9): 1134-1149.
|
38. |
程能能. 我国首个原研口服抗HBV药物TMF结构优势解读—神奇的甲基化. 肝脏, 2021, 26(12): 1303-1305.
|
39. |
刘桂杰, 王力, 陈砚鑫, 等. TACE联合干扰素α治疗晚期原发性肝癌疗效观察. 山东医药, 2010, 50(18): 109-110.
|
40. |
黄得校, 陈勇, 曾庆乐, 等. 大剂量干扰素联合化疗药物经导管动脉化疗栓塞术对肝癌患者T细胞亚群的影响. 广东医学, 2013, 34(20): 3185-3188.
|
41. |
张琼华, 施光峰, 李谦, 等. 甘草酸二铵肠溶胶囊治疗慢性肝炎2 396例. 中华传染病杂志, 2007, 25(3): 175-176.
|